OR WAIT null SECS
March 27, 2018
In a $13-billion transaction, GSK will purchase Novartis’ share of the Consumer Healthcare Joint Venture.
March 26, 2018
Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.
March 23, 2018
The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
March 22, 2018
Helsinn will acquire the global rights to Valchlor/Ledaga (mechlorethamine/chlormethine), a topical skin-cancer drug, from Actelion Pharmaceuticals.
March 21, 2018
AbbVie and the International Myeloma Foundation will partner to study the role of a genetic mutation in outcomes of patients with multiple myeloma.
March 19, 2018
Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.
The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.
March 13, 2018
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
March 09, 2018
The European Medicines Agency has called for the immediate suspension and recall of AbbVie and Biogen's multiple sclerosis drug Zinbryta (daclizumab beta).
March 08, 2018
Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.